Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The evidence bases are comparable in quality and scale, with both lacking large-scale randomized therapeutic trials
The Honest Answer At normal therapeutic doses, supervised by a qualified doctor, with branded pharmaceutical-grade vials, the safety profile is reasonable
This is risky for several reasons: Wrong patient selection, such as people with pancreatitis, gallstones, or severe kidney disease using them without screening Rapid, unsupervised dose escalation No monitoring of kidney, liver, pancreatic, or eye status Complications seen with unsupervised use include pancreatitis, dehydration-induced acute kidney injury (especially in hot Indian summers with vomiting or diarrhoea), and even diabetic ketoacidosis in susceptible individuals
Resmetirom (Rezdiffra TM ), a liver-directed thyroid hormone receptor- (THR-) agonist, received accelerated FDA approval in March 2024 as the first agent specifically indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3), based on the MAESTRO-NASH trial demonstrating MASH resolution and fibrosis improvement
